KRS Capital Management LLC Sells 195 Shares of IQVIA Holdings Inc. (NYSE:IQV)

KRS Capital Management LLC lessened its position in IQVIA Holdings Inc. (NYSE:IQV) by 9.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,765 shares of the medical research company’s stock after selling 195 shares during the quarter. KRS Capital Management LLC’s holdings in IQVIA were worth $446,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. AdvisorNet Financial Inc increased its stake in IQVIA by 327.6% in the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 95 shares during the last quarter. Rise Advisors LLC purchased a new stake in IQVIA during the first quarter valued at about $31,000. Riverview Trust Co purchased a new stake in IQVIA during the first quarter valued at about $32,000. BKM Wealth Management LLC purchased a new stake in IQVIA during the fourth quarter valued at about $32,000. Finally, Activest Wealth Management purchased a new stake in IQVIA during the fourth quarter valued at about $35,000. Institutional investors own 89.62% of the company’s stock.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Truist Financial cut their price target on shares of IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a research report on Friday, May 3rd. Evercore ISI dropped their target price on shares of IQVIA from $275.00 to $250.00 and set an “outperform” rating for the company in a report on Friday, May 3rd. Robert W. Baird dropped their target price on shares of IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a report on Friday, May 3rd. The Goldman Sachs Group began coverage on shares of IQVIA in a report on Thursday, June 6th. They set a “buy” rating and a $270.00 target price for the company. Finally, StockNews.com upgraded shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday. Three investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $257.73.

IQVIA Stock Down 0.6 %

Shares of NYSE IQV traded down $1.31 on Friday, reaching $211.44. 5,448,174 shares of the company’s stock traded hands, compared to its average volume of 1,310,028. IQVIA Holdings Inc. has a 12 month low of $167.42 and a 12 month high of $261.73. The business’s 50 day simple moving average is $223.93 and its two-hundred day simple moving average is $230.06. The company has a market cap of $38.52 billion, a price-to-earnings ratio of 28.87, a price-to-earnings-growth ratio of 1.94 and a beta of 1.53. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, May 2nd. The medical research company reported $2.30 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.11. The company had revenue of $3.74 billion during the quarter, compared to the consensus estimate of $3.69 billion. IQVIA had a net margin of 9.01% and a return on equity of 29.17%. As a group, equities research analysts forecast that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.